Introduction: Endometrial polyps (EP) are common within the gynaecological practice. The aims of this study are to evaluate the risk of premalignant and malignant changes in EP and to determine the predictors of histological outcomes of these lesions.
INTRODUCTION
Endometrial polyp (EP) is a common presentation within the gynaecological practice. It is the most frequent endometrial finding in menopausal women [1] . It is usually benign [2] but may be associated with malignancy [3] . Women commonly present with abnormal uterine bleeding but a few are asymptomatic, discovered at routine ultrasound investigations for other reasons including infertility [2, [4] [5] . Its prevalence is 7.8% within the population, increasing with age [6] . They are diagnosed in 5.8% of pre and 11.8% of postmenopausal women [6] . Lieng et al. [7] in their systematic review described a pooled prevalence of 0.8% and 3.1% of premalignant and malignant tissue changes respectively within polyps. The prevalence of malignancy varies significantly with age and menopausal status [7] [8] [9] [10] [11] [12] , with the postmenopausal group of patients presenting with abnormal uterine bleed having the highest risk of premalignant and malignant tissue changes [7] [8] 13] . Lee et al. [14] in their meta-analysis reported a prevalence of 5.42% and 1.7% for premalignant and malignant polyps respectively for postmenopausal women in general [14] . There are conflicting reports on the sizes of polyps that might be relevant as a predictor of malignancy. Some studies have shown sizes of greater than 15mm [11] and 18mm as significant factors for premalignant and malignant changes [15] . Endometrial polyps represent the most common endometrial pathology associated with postmenopausal tamoxifen use [16] . The use of tamoxifen predisposes patient to the development of EPs [16] [17] and polyps tend to be larger for those taking tamoxifen compared to those that are not [18] . Kennedy and colleagues described the histological features as characteristically multiple and fibrotic, with a high rate showing malignant change [17] .
he aims of this study are to evaluate the risk of premalignant and malignant changes in EPs and to determine predicators of histological outcomes of these lesions.
MATERIALS AND METHODS
This is a retrospective study conducted over a 12-year period between 2000 and 2012 at Singleton hospital, a major district hospital in South Wales, United Kingdom. Data were retrieved from patients' and theatre records. The histopathology reports in all cases were retrieved. All cases with confirmed EP at hysteroscopy were identified. These include all pre and postmenopausal women who had endometrial polyps confirmed at hysteroscopy within the study period. Data analysed include the age, polyp size, and menopausal status. Data were also retrieved on use of hormone replacement therapy (HRT), current use of tamoxifen and histology results. Women were considered menopausal if they reported amenorrhea of at least 12 months after the age of 45 years. Abnormal uterine bleeding was defined as vaginal bleeding in postmenopausal women not receiving HRT or as irregular vaginal bleeding in women still actively menstruating or being treated with HRT. Histology results were classified as benign, pre-malignant, and malignant. Cases with simple and complex hyperplasia without atypia were classified as benign. 'Pre-malignant' refers to hyperplastic endometrium with atypia while 'malignant' were patients diagnosed with endometrial cancer In the analysis, abnormal histology refers to number of cases with malignant changes plus number of polyps with premalignant changes at histological examination. Results are presented as mean+/-S.D.
Data were analysed using IBM SPSS Statistics 20 to determine Chi square and risk ratio. The level of statistical significance at which the null hypothesis was rejected was chosen at 0.05.
RESULTS
There were 397 cases of polyps confirmed at hysteroscopy. The age range was between 24 and 89 years with a median age of 54 years. 56% of patients were postmenopausal; and 88% of all the cases were done as day case procedures. 12 patients had been on tamoxifen at the time of presentation, while 17 patients were on HRT. The Table 1 below describes the symptoms patients presented with and the histological outcomes.
Postmenopausal bleeding accounted for about 53% of the cases. 8 patients had endometrial polyps confirmed at hysteroscopy as part of their investigations for infertility. There was one patient with EP confirmed at hysteroscopy for recurrent vaginal discharge.
Patients' symptoms at presentation varied particularly with age; patients presenting with postmenopausal bleeding were 53% of the entire cohort and dysfunctional uterine bleeding made up 37% of the cases. The prevalence of malignant EP in premenopausal women was 0.6%, increasing to 2.1% in postmenopausal women. (Tables 2 and 3 ). Data were analysed to determine if there was an association with increasing sizes of the polyp and abnormal histology/premalignancy. There was no association between increasing polyp size and abnormal histology see (Table 2 ) or premalignancy ( Table 3) . 
DISCUSSION
EP remains a common presentation in gynaecological practice. There is variation in the management of EP especially when they are incidental findings while investigating for other conditions. This is a study of women with EP over a period of 12 years. Approximately 12% of diagnosed cases had premalignant and malignant changes confined to polyps. About 11% of cases had hyperplasia with atypia while 1.5% of patients had carcinoma confined to EP. Our study analysed size of polyp in two ways: (i) absolute sizes i.e. <15mm or >15mm and (ii) at intervals of 10mm. There is no previous study in the literature that has analysed the size of EP in this way. There was no association with abnormal histology or premalignancy in either sub-group. Age was a significant predictor of abnormal histology. Older women have a higher chance of abnormal histology. 25% of patients over the age of 60 years were diagnosed with premalignant and malignant changes at histology. Patients over 60 years were twice as likely to have abnormal or premalignant changes at histology compared with patients below 60 years. This is similar to many previous studies [7] [8] [9] 11] . Antunes and colleagues claimed that postmenopausal women over 60 years were 5 times more likely to have premalignant and malignant changes in EP [9] . Menopausal status is a strong predictor of abnormal histology. In their meta-analysis, Lee and associates identified this as predictor for malignancy [14] . Our study showed that postmenopausal women were almost twice as likely to have premalignant/malignant polyp as premenopausal women. Our study also showed that increasing age is a predictor of abnormal histology, which is similar to findings by previous studies in the literature [7] [8] [9] 11] .
Postmenopausal bleeding is also a relevant predictor, with women presenting with the symptom twice as likely to have premalignant or malignant changes at histology compared to women with other symptoms There was no association between tamoxifen or use of hormone replacement therapy (HRT) and premalignant or malignant changes in polyps. These findings differ from that other of other studies [19] [20] . This discrepancy may be due to the relatively small numbers of patients on tamoxifen and HRT in our study.
Patients that are asymptomatic are unlikely to have premalignant or malignant changes of EP. The diameter of the polyp was not significant in the prediction of abnormal histology. Ferrazzi and colleagues, in their series, revealed that polyps greater than 18mm were likely to be associated with abnormal histology [15] . The difference in findings might be due to relatively small number of asymptomatic cases in our study compared to their study.
In conclusion, patients over the age of 60 years, menopausal status and postmenopausal bleeding are predictors of abnormal histology in endometrial polyps. This is the first study in the literature to evaluate increasing polyp size relative to abnormal histology and premalignancy. Our study shows that there is no association between these parameters. Patients and clinicians should be aware of these findings when making decisions on the clinical management of EP.
